Baldur Sveinbjornsosn
Chief Scientific Officer Lytix Biopharma AS
Dr. Sveinbjørnsson achieved his doctorate at the Medical Faculty of the University of Tromsø in 1998, with a focus on mechanisms and mediators behind immunomodulation of experimental tumors. Since then, Dr. Sveinbjørnsson has gained a broad expertise of preclinical oncology at the University of Tromsø and Karolinska Institutet Stockholm.
Dr. Sveinbjørnsson has been involved in the research activities of Lytix Biopharma since the beginning, and has most recent years led the Company’s research activities as Chief Scientific Officer.
Seminars
Wednesday 2nd December 2026
Evidence – Understanding Which Models Best Predict Systemic Responses to Intratumoral Immunotherapies
3:40 pm
- Exploring the limitations of traditional tumour models when evaluating immunemediated mechanisms of action
- Assessing how models can capture tumour antigen release, immune priming, and responses beyond the treated tumour site
- Applying translational learnings from intratumoral immunotherapy development to improve combination strategies and clinical translation
Wednesday 2nd December 2026
Insights Exchange – What Biological Features Are Still Missing From Today’s Tumour Models?
5:00 pm
- Which aspects of the tumour microenvironment remain most difficult to capture?
- How can advanced models be made more scalable and reproducible?
- What innovations will have the biggest impact on model relevance over the next five years?
- Audience Q&As
